<DOC>
	<DOCNO>NCT00176735</DOCNO>
	<brief_summary>Pancreatic cancer traditionally treat chemotherapy radiation therapy limit result . Preliminary study part program patient advance pancreatic cancer produce favorable result acceptable side effect . We feel treatment sequence may help slow and/or control growth pancreatic cancer . This study help doctor learn whether pancreatic cancer respond treatment . This study use combination two chemotherapy drug , gemcitabine cisplatin , treatment radiation therapy oral chemotherapy drug call capecitabine . This sequence combination chemotherapy radiation therapy , radiation therapy drug capecitabine study . Parts sequence , example , combination gemcitabine cisplatin , show promising result treatment pancreatic cancer . This research study attempt combine various part .</brief_summary>
	<brief_title>Capecitabine Radiation Therapy Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Eligibility Criteria 1 . Patients must cytologic histologic confirmation pancreatic carcinoma . 2 . Patients must unresectable disease without distant metastasis . A status unresectable base review helical CT scan surgical consultation . 3 . Patients history previous abdominal irradiation chemotherapy pancreatic cancer ineligible . 4 . Patients must estimate life expectancy least 12 week Zubrod performance status ≤ 2 ( appendix I ) . 5 . Patients must 18 year age old . Patients reproductive potential must agree use effective contraceptive method treatment . 6 . Patients must adequate organ function define follow : bone marrow granulocytes ≥ 1500/cmm , platelet &gt; 100,000/cmm , renal serum Cre &lt; 1.5 mg/dl , hepatic bilirubin &lt; 3 mg/dl . 7 . Patients must free active systemic malignancy serious comorbid medical psychiatric condition would interfere safe delivery protocol therapy . 8 . Patients must aware investigational nature therapy provide write informed consent per institutional guideline prior initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>